Jassim al Khaja K A, Sequeira R P, Wahab A W, Mathur V S
Department of Pharmacology & Therapeutics, College of Medicine & Medical Sciences, Arabian Gulf University, Bahrain, P.O. Box No. 22979.
Pharmacoepidemiol Drug Saf. 2001 May;10(3):219-27. doi: 10.1002/pds.578.
To determine the antihypertensive drug prescribing pattern by primary care physicians in patients with uncomplicated essential hypertension; to identify whether such pattern of prescription is appropriate and in accordance with international guidelines for pharmacotherapy of hypertension; and to estimate the impact of such prescriptions on cost of treatment.
A prescription-based survey among patients with uncomplicated essential hypertension was conducted in seven out of a total of 18 health centres in Bahrain. The relevant data for our study was collected using cards, designed for chronically-ill patients.
A total of 1019 male and 1395 female (62.9%) out of 3838 of the study population were on monotherapy, whereas 596 male and 828 female (37.1%) were on antihypertensive combination therapy. Among the monotherapy category, the various antihypertensive drugs used were as follows: beta-blockers (58.8%), angiotensin converting enzyme (ACE) inhibitors (14.2%), calcium channel blockers (11.1%), diuretics (8.1%) and alpha-methyldopa (7.0%). With respect to overall utilization pattern, beta-blockers were the most frequently prescribed (65.5%), diuretics ranked second (27.4%), followed by ACE inhibitors (20.6%), calcium channel blockers (19.9%) and alpha-methyldopa (8.5%). Within each class of antihypertensives used, the most frequently used individual agents were as follows: (a) among beta-blockers 97.7% used atenolol; (b) among the diuretics, indapamide (35.4%), hydrochlorothiazide (HCTZ) (32.7%), HCTZ in combination with triamterene (25.7%), and chlorthalidone (4.6%); (c) among the ACE inhibitors, captopril (44.9%), enalapril (29.7%), and lisinopril (19.0%); (d) among the calcium channel blockers, nifedipine (98.2%). Significant age- and gender-related differences in prescribing patterns were seen. Short-acting nifedipine monotherapy was inappropriately prescribed in a significant number of patients above the age of 50 years. ACE inhibitors accounted for approximately two-thirds of the total antihypertensive drug expenditure, although these drugs represent only one-fifth of overall antihypertensives used. There is a trend towards excessive use of expensive thiazide-like diuretics such as indapamide which seems to be unjustifiable practice, particularly in a study population free from diabetic hypertensive patients.
The general pattern of antihypertensive utilization appears to be in accordance with the guidelines of WHO and the Joint National Committee issued in the 1990s. The trends of prescribing of antihypertensives were in favour of conventional ones such as the beta blockers and diuretics, and the introduction of newer classes of antihypertensives had a generally minimal impact on the prescribing profile. Almost two-thirds of the patients were treated with monotherapy. A disproportionately large percentage of antihypertensive drug cost was due to overt use of ACE inhibitors, and indapamide, instead of thiazide diuretics. The use of short-acting calcium channel blockers especially in the elderly is unjustifiable.
确定基层医疗医生对单纯性原发性高血压患者的降压药物处方模式;确定这种处方模式是否恰当并符合高血压药物治疗的国际指南;并评估此类处方对治疗费用的影响。
在巴林总共18个健康中心中的7个对单纯性原发性高血压患者进行了一项基于处方的调查。我们研究的相关数据使用为慢性病患者设计的卡片收集。
在3838名研究人群中,共有1019名男性和1395名女性(62.9%)接受单一疗法,而596名男性和828名女性(37.1%)接受降压联合疗法。在单一疗法类别中,使用的各种降压药物如下:β受体阻滞剂(58.8%)、血管紧张素转换酶(ACE)抑制剂(14.2%)、钙通道阻滞剂(11.1%)、利尿剂(8.1%)和α-甲基多巴(7.0%)。就总体使用模式而言,β受体阻滞剂是最常处方的药物(65.5%),利尿剂排名第二(27.4%),其次是ACE抑制剂(20.6%)、钙通道阻滞剂(19.9%)和α-甲基多巴(8.5%)。在每一类使用的抗高血压药物中,最常用的个体药物如下:(a)在β受体阻滞剂中,97.7%使用阿替洛尔;(b)在利尿剂中,吲达帕胺(35.4%)、氢氯噻嗪(HCTZ)(32.7%)、HCTZ与氨苯蝶啶联合使用(25.7%),以及氯噻酮(4.6%);(c)在ACE抑制剂中,卡托普利(44.9%)、依那普利(29.7%)和赖诺普利(19.0%);(d)在钙通道阻滞剂中,硝苯地平(98.2%)。在处方模式上观察到了显著的年龄和性别差异。大量50岁以上的患者不恰当地使用了短效硝苯地平单一疗法。ACE抑制剂占抗高血压药物总支出的约三分之二,尽管这些药物仅占所用抗高血压药物总数的五分之一。有一种过度使用昂贵的噻嗪类利尿剂如吲达帕胺的趋势,这似乎是不合理的做法,特别是在没有糖尿病高血压患者的研究人群中。
抗高血压药物使用的总体模式似乎符合世界卫生组织和20世纪90年代发布的美国国家联合委员会的指南。抗高血压药物的处方趋势有利于传统药物,如β受体阻滞剂和利尿剂,新类别的抗高血压药物的引入对处方情况的总体影响最小。几乎三分之二的患者接受单一疗法治疗。抗高血压药物成本中不成比例的很大一部分是由于过度使用ACE抑制剂和吲达帕胺,而不是噻嗪类利尿剂。尤其是在老年人中使用短效钙通道阻滞剂是不合理的。